The global pandemic of the novel coronavirus disease
(COVID-19) has had a significant impact on adult and pediatric
patients with many acute and chronic diseases including cancer.
The purpose of this correspondence is to project the challenges
faced by both, the children undergoing treatment and the
treating pediatric oncologist [1].
Providing medical care to children with cancer during this
pandemic is challenging given the risks of death from cancer
versus death or serious complications in the
immunocompromised hosts [2,3]. Hospitals are delaying
chemotherapy, radiotherapy and surgery after being overwhelmed
by COVID-19 infection.
Patients with cancer also fear coming to hospital fearing
the risk of infection. There are also limited supplies of
personal protective equipment (PPE) for doctors and other
personnel, limited beds and ICU facility, limited blood bank
facilities and also strained diagnostic facilities. Limited
data, though from adults, also suggests that cancer patients
with COVID will fare worse [4]. In a study from China, there was
a higher risk of severe events in COVID-19 patients with cancer
compared with those without cancer. Theoretically, immune
therapy can result in cytokine release and worsen the viral
injury, which is also believed to be due to a cytokine storm,
but this is a theoretical consideration and not proven due to
very limited data.
Some general guidelines have been provided for children with
cancer [5], which include, in addition to social distancing,
mask usage outside home and hygiene, viz. clinic visits
that can be postponed without risk to the patient should be
postponed and telemedicine to be used to screen and evaluate
patients. Certain other issues are briefly elucidated herein.
Difficulty in hospital consultation:
Many hospitals have been designated as centers for management of
COVID-19, leading to temporary stoppage of outpatient services.
Children with malignancies are unable to come for outpatient
consultation for clinical follow-up and chemotherapy planning.
In addition, it is now difficult for outstation patients to
visit referral centers, despite prior appointments.
New cases needing evaluation are also not able to reach some of
the major hospitals,which have temporarily closed OPD
registrations to focus on COVID patients. There is also risk of
new patients being asymptomatic carriers, but the current
guidelines do not allow COVID testing for all new hospital
admissions even if they are immune-compromised cancer patients.
Increased risk of coronavirus infection:
The pandemic poses a risk of coronavirus infection for all
individuals including children. Children with cancer are assumed
to be more susceptible to the coronavirus due to inherent
suppressed immune function associated with cancer treatment and
repeated attendance in health care facilities [2].
Treatment delay:
Children with cancer, already on treatment, were advised to stay
indoors and practice social distancing resulting in delay in
their treatment. The nationwide lockdown further delayed the
treatment due to restricted mobility even within the city or
travel from outstation. The bed strength available for in-house
admission has also reduced due to diversion to COVID-19 wards,
leading to delayed/deferred intensive chemo-therapies requiring
in-house management [5]. Most hospitals have split the staff
into two or more teams so as to reduce chances of infection and
keep a reserve pool of medical staff, should one team be exposed
to a COVID case. A drawback has been the increased workload for
treating teams, and the possibility of delay in getting
appointment for investigations/procedures.
Shortage of blood
component:
The lockdown has drastically reduced the number of voluntary
blood donations, thereby creating a shortage at blood banks. In
addition, relatives of patients have also been unable to come
for donations due to travel restrictions. This problem has also
been highlighted in centers treating thalassemia patients [6].
Social impact:
The COVID -19 pandemic has caused stress to families resulting
from the infection itself, delayed treatment, need of prolonged
unexpected stay due to lockdown, lack of availability of
accommodation and financial implications. Patients often need
travel passes and travel support from treating physician and
NGOs to be able to come to hospitals for treatment.Some are not
willing to come for treatment for fear of contacting corona
infection.
In a recent online publication [7],
it was stated that there is no reason to discontinue daily
activities in pediatric hematology/oncology units or to turn
away children with suspected cancer during this pandemic. It
seems desirable to postpone high intensity treatments, where
feasible, and to prepare to triage according to prognosis.
Similar treatment advice has also been released online recently
by Tata Memorial Hospital, Mumbai. It may be highlighted that
the rarity of cases reported precludes the development of clear
chemotherapy guidelines for children being treated for cancer.
In summary, delivering cancer care
during the pandemic is challenging given the risks of death from
cancer versus death from infection. The likelihood of a
severe illness from COVID-19 is higher among patients with
cancer. As more information becomes available evidence-based
consensus recommendations may emerge. Individual centers
treating childhood cancers may come up with strategies to tackle
the situation. A balance needs to be created keeping in mind
risks associated with COVID-19 and the timely management of a
child with cancer [8].
Funding:
None; Competing interest: None stated.
REFERENCES
1. Yang C, Li C, Wang S,
National Clinical Research Center for Child H, Disorders,
Children’s Oncology Committee of Chinese Research Hospital A.
Clinical strategies for treating pediatric cancer during the
outbreak of 2019 novel coronavirus infection. Pediatr Blood
Cancer. 2020;67: e28248.
2. Yu J, Ouyang W, Chua
MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a
tertiary care hospital in Wuhan, China. JAMA Oncol. 2020 Mar 25.
[Epub ahead of print]. Available from:
https://jamanetwork.com/journals/jamaoncology/fullarticle/2763673.Accessed
May 2, 2020.
3. Lewis MA. Between Scylla
and Charybdis - Oncologic decision making in the time of
Covid-19. N Engl J Med. 2020 Apr 7. [Epub ahead of print].
Available from:https://www.nejm.org/doi/full/10.1056/NEJMp2006588.
Accessed May 2, 2020.
4. Xia Y, Jin R, Zhao J, Li
W, Shen H. Risk of COVID-19 for patients with cancer. Lancet
Oncol.2020;21:e180. Available from:
https://www.thelancet.com/journals/lanonc/article/
PIIS1470-2045(20)30149-2/fulltext. Accessed May 2, 2020.
5. Cinar P, Kubal T,
Freifeld A, Mishra A, Shulman L, Bachman J, et al. Safety
at the time of the COVID-19 Pandemic: How to keep our oncology
patients and healthcare workers safe. J Natl ComprCanc
Netw. 2020 Apr 15:1-6. Available from:
https://jnccn.org/view/
journals/jnccn/aop/article-10.6004-jnccn.2020.7572/article-10.6004-jnccn.2020.7572.xml.
Accessed May 2, 2020.
6. Yadav U, Pal R.
Challenging Times for Children With Transfusion-dependent
Thalassemia Amid the COVID-19 Pandemic. Indian Pediatrics. April
07, 2020. [Epub ahead of print]. Available from:
https://indianpediatrics.net/COVID29.03.2020/CORR-00155.pdf.Accessed
May 2, 2020.
7. Bouffet E, Challinor J,
Sullivan M, Biondi A, Rodriguez Galindo C, Pritchard Jones K.
Early advice on managing children with cancer during the COVID
19 pandemic and a call for sharing experiences. Pediatr Blood
Cancer. 2020 Apr 2:e28327. Available from: https://
onlinelibrary.wiley.com/doi/full/10.1002/pbc.28327. Accessed
May 2, 2020.
8. Chen Z, Xiong H, Li JX,
Li H, Tao F, Yang YT, et al. [COVID-19 with
post-chemotherapy agranulocytosis in childhood acute leukemia: a
case report] [Chinese]. ZhonghuaXue Ye XueZaZhi. 2020 Mar
9;41:E004. Available from: http://journal.yiigle.
com/LinkIn.do?linkin
_type=pubmed&DOI=10.3760/cma.j.issn.0253-2727. 2020.0004.Accessed
May 2, 2020.